These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Current pathophysiological views on vibration-induced Raynaud's phenomenon. Stoyneva Z; Lyapina M; Tzvetkov D; Vodenicharov E Cardiovasc Res; 2003 Mar; 57(3):615-24. PubMed ID: 12618223 [TBL] [Abstract][Full Text] [Related]
15. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension. Wigley FM Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460 [TBL] [Abstract][Full Text] [Related]
16. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Planchon B; Pistorius MA; Beurrier P; De Faucal P Angiology; 1994 Aug; 45(8):677-86. PubMed ID: 8048777 [TBL] [Abstract][Full Text] [Related]
17. Digital blood flow response to body warming, cooling, and rewarming in patients with Raynaud's phenomenon. Lau CS; Khan F; Brown R; McCallum P; Belch JJ Angiology; 1995 Jan; 46(1):1-10. PubMed ID: 7818151 [TBL] [Abstract][Full Text] [Related]
18. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Sunderkötter C; Riemekasten G Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831 [TBL] [Abstract][Full Text] [Related]
19. Secondary Raynaud's phenomenon is associated with microvascular peripheral endothelial dysfunction. Taher R; Sara JD; Toya T; Shepherd R; Moder K; Lerman LO; Lerman A Microvasc Res; 2020 Nov; 132():104040. PubMed ID: 32768463 [TBL] [Abstract][Full Text] [Related]
20. Raynaud's phenomenon: from molecular pathogenesis to therapy. Prete M; Fatone MC; Favoino E; Perosa F Autoimmun Rev; 2014 Jun; 13(6):655-67. PubMed ID: 24418302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]